Clinical Trials Directory

Trials / Completed

CompletedNCT05723978

Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.

Status
Completed
Phase
Study type
Observational
Enrollment
520 (actual)
Sponsor
Tianjin Medical University Cancer Institute and Hospital · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with relatively poor survival. Surgery is the first choice for the treatment of patients with early pancreatic cancer. However, the surgical approach and the extent of resection for patients with pancreatic cancer are controversial at present. The investigators optimized the procedure of standard pancreaticoduodenectomy to selective extended dissection (SED), which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor. The investigators retrospectively analyzed the clinicopathological data of patients with pancreatic adenocarcinoma who underwent radical surgery in our center from 2011 to 2020. Patients who underwent standard dissection (SD) were matched 2:1 to those who underwent SED using propensity score matching (PSM). The log-rank test and cox regression model were used to analyze survival data. In addition, statistical analyses were performed for the perioperative complications, postoperative pathology and recurrence pattern.

Conditions

Interventions

TypeNameDescription
PROCEDURESelective extended dissection of pancreaticoduodenectomyAn optimized procedure of pancreaticoduodenectomy which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor.

Timeline

Start date
2011-01-01
Primary completion
2022-07-01
Completion
2022-12-01
First posted
2023-02-13
Last updated
2023-02-13

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05723978. Inclusion in this directory is not an endorsement.